Phase II study of sunitinib in metastatic transitional cell carcinoma of the urothelium

Trial Profile

Phase II study of sunitinib in metastatic transitional cell carcinoma of the urothelium

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2016

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 05 Mar 2010 Results of biomarker analysis presented at ASCO Genitourinary Cancers Symposium 2010.
    • 08 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top